We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
MGI Pharma Inc. and SuperGen Inc. have withdrawn their application for European marketing authorization for an experimental drug, the companies said Tuesday.
The stringent regulatory environment in the Gulf Co-Operation Council (GCC) region is having a negative affect on Indian pharmaceutical exporters, according to industry sources.
The Colombian government should change its drug pricing system, as a comprehensive reimbursement system would be preferable to the threat of direct price controls.
Although drug exports are showing robust growth, imports continue to dominate the Croatian pharmaceuticals market, accounting for around 50% of the sector compared to roughly 20-35% just a few years ago.
Biovail Corp. declared its first dividend Tuesday and said it intends to spin off its branded off-patent drug products -- or "legacy" assets -- into a new company owned by current Biovail shareholders.
Ariad Pharmaceuticals Inc. said Tuesday that European regulators granted "orphan drug" status to its experimental treatment for soft-tissue and bone cancers, a designation the therapy already has in the United States.
GW Pharmaceuticals Plc, a developer of cannabis-based medicines, said the U.K. will allow limited imports of its unlicensed multiple sclerosis drug, Sativex, from Canada.
Pharmaxis Ltd announced today that the European Medicines Agency (EMEA) has granted Orphan designation to the company's product Bronchitol(TM), for the treatment of cystic fibrosis.
Despite failed attempts to acquire foreign pharma companies, three Indian pharma majors Ranbaxy, Wockhardt and Nicholas Piramal are now looking at acquiring Germany's fourth largest generic firm, betapharm Arzneimittel GmbH.